December 6th 2024
Through the agreement, Cambrex will provide accelerated access to clinical development capabilities to Lilly’s biotech collaborators.
AMB-05X Receives EMA PRIME Designation for Treatment of Tenosynovial Giant Cell Tumor
January 20th 2023The efficacy data across multiple clinical endpoints and a favorable safety profile support the potential of AMB-05X as a best-in-class therapy for the treatment of TGCT regardless of surgical resectability.
Medigene Receives Historic $3 Million Payment from 2seventy Bio
January 18th 2023Recently, 2seventy bio announced the initiation of a strategic partnership with JW Therapeutics aiming at the collaboration being the development of 2seventy bio’s MAGE-A4 cell therapy in mainland China, Hong Kong, and Macao.